Previous 10 | Next 10 |
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $18PT. Our assumptions include: Launch of the glucagon re...
Gainers: Camber Energy (NYSEMKT: CEI ) +61% . More news on: Camber Energy, Inc., Cancer Genetics, Inc., Micron Solutions, Inc., Stocks on the move, , Read more ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced a limited-time $0 copay offering for commercially eligible...
GVOKE Pre-Filled Syringe (PFS) is available for home delivery through PillPack by Amazon Pharmacy Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable an...
Image source: The Motley Fool. Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Q4 2019 Earnings Call Mar 11, 2020 , 8:30 a.m. ET Operator Continue reading
Xeris Pharmaceuticals, Inc. (XERS) Q4 2019 Results Earnings Conference Call March 11, 2020, 08:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations and Corporate Communications Paul Edick - Chairman & Chief Executive Officer Barry Deutsch - ...
Xeris Pharmaceuticals (NASDAQ: XERS ): Q4 GAAP EPS of -$1.23 misses by $0.08 . Revenue of $1.63M beats by $0.97M . Shares +4% PM. Press Release More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
GVOKE™ PFS net sales of $1.6 million in Q4 2019 GVOKE HypoPen™ on track for planned launch in July 2020 All current clinical programs expected to report topline results in 1H 2020 Conference call and webcast today at 8:30 a.m. ET Xeris Pharmaceuticals, In...
CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Comp...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that, in connection with its previously announced underwritten public ...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...